Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Você mais próximo do European Respiratory Society Meeting. Confira os principais destaques do terceiro dia do evento. 

Estudo Salford: Efetividade no tratamento da Asma

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170913_Respiratorio_ERS_David_Leather.mp4

Entenda como Relvar contribui para o melhor controle da asma na vida real. Assista os comentários sobre a publicação do The Lancet com o Dr. David Leather, líder do estudo (SLS) da GSK.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170913_Respiratorio_ERS_Oliver_Nascimento.mp4

Conheça mais sobre a relação entre a DPOC e doenças cardiovasculares, biomarcadores e tratamento.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170913_Respiratorio_ERS_Neil_Barnes.mp4

Medicina personalizada para doenças respiratórias com o Dr. Neil Barnes, Líder da Franquia Respiratória GSK.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170913_Respiratorio_ERS_Bernardo_Maranhao.mp4

Novas pesquisas em Asma e DPOC que foram tema do ERS. Assista.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/20170913_Respiratorio_ERS_Marcelo_Tadday.mp4

O impacto da gestação na asma e o seu tratamento. Confira.

  • Entrevista Dr. Neil Barnes
    1. MILES, EA. et al. Can Early Omega-3 Fatty Acid Exposure Reduce Risk of Childhood Allergic Disease? Nutrients, 9(7), 2017. Epub. Disponível em: <http://www.mdpi.com/2072-6643/9/7/784>. Acesso em: 12 set. 2017.
    2. WOLSK, HM. et al. Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial. J Allergy Clin Immunol, 2017. Epub. Disponível em: <https://www.ncbi.nlm.nih.gov/m/pubmed/28285844/>. Acesso em: 13 set. 2017.
    3. CHUNG, K. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 43(2): 343-73, 2014.
    4. GLOBAL INITIATIVE FOR ASTHMA. Global strategy for asthma management and prevention. Updated 2017. Disponível em: <http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/>. Acesso em: 13 set. 2017.
    5. WANG, Z. et al. Bronchiectasis: still a problem. Chin Med J (Engl)., 127(1): 157-72, 2014.
    6. AUGUSTI, A. et al. Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns. Chronic Obstr Pulm Dis, 1(2): 166–184, 2014.

    BR/RESP/0128/17 – Setembro/2017

    Entrevista Dr. David Leather
    1. WOODCOCK, A. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet, 2017. Epub. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0140673617323978>. Acesso em: 12 set. 2017.
    2. VAN der PALEN, J. et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. npj Primary Care Respiratory Medicine, 26: 16079, 2016.

    BR/RESP/0128/17a – Setembro/2017

    Entrevista Dr. Oliver Nascimento
    1. VANFLETEREN, LEGW. et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med, 4(11): 911-924, 2016.
    2. MARTINIS, M. et al. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol, 80(3): 219-227, 2006.
    3. VANFLETEREN, LGWE. et al. Clusters of Comorbidities Based on Validated Objective Measurements and Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 187(7): 728-735, 2013.
    4. BORLAUG, BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol, 11(9): 507-15, 2014.
    5. GARCIA-SANZ, MT. et al. One-year and long-term mortality in patients hospitalized for chronic obstructive pulmonary disease. J Thorac Dis, 9(3): 636-645, 2017.
    6. ROCA, M. et al. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest, 43(5): 510-21, 2013.
    7. BERGHE, B. et al. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J, 41: 993-995, 2013.
    8. CONTOLI, M. et al. Inhaled Corticosteroid/Long-Acting Bronchodilator Treatment Mitigates STEMI Clinical Presentation in COPD Patients. Eur J Intern, 2017. Epub. Disponível em: <https://www.ncbi.nlm.nih.gov/labs/articles/28821412/>. Acesso em: 12 set. 2017.
    9. SHORT PM. et al. Beta-Blockers Reduce Mortality and Exacerbations When Added to Stepwise Inhaled Therapy for COPD Without Adverse Effects on Lung Function. Am J Respir Crit Care Med, 183: A2630, 2011.
    10. ROTHNIE, KJ. et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open, 5(9): e007824, 2015.
    11. BERNASCONI, M. et al. Midregional Proatrial Natriuretic Peptide Predicts Survival in Exacerbations of COPD. Chest, 140(1): 91-99, 2011.
    12. PAVASINI R. et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. Int J Cardiol, 191: 187–193, 2015.
    13. HAWKINS, NM. et al. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med, 17:11, 2017.
    14. BRUNNER LA ROCCA, HP. et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail, 17(12): 1252-61, 2015.
    15. CALVERLEY, PMA. et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax, 65(8): 719-725, 2010.
    16. VESTBO, J. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomized controlled trial. Lancet, 387: 1817-26, 2016.
    17. TASHKIN D. et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Eng J Med, 359: 1543, 2008.
    18. WATZ, H. et al. Decreasing Cardiac Chamber Sizes and Associated Heart Dysfunction in COPD: Role of Hyperinflation. Chest, 138: 32-38, 2010.
    19. STONE, IS. et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med, 193(7): 717-26, 2016.

    BR/RESP/0128/17b – Setembro/2017

    Entrevista Dr. Bernardo Maranhão
    1. AARON, SD. et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA,317(3): 269-279, 2017.
    2. MURPHY, PB. et al. Effect of Home Noninvasive Ventilation with Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA,317(21): 2177-2186, 2017.
    3. MARCON, A. et al. Can an airway challenge test predict respiratory diseases? A population-based international study. J Allergy Clin Immunol, 133(1): 104-10, 2014.

    BR/RESP/0128/17c – Setembro/2017

    Entrevista Dr. Marcelo Tadday
    1. ALI, Z. et al. Excessive gestational weight gain in first trimester is a risk factor for exacerbation of asthma during pregnancy: A prospective study of 1283 pregnancies. J Allergy Clin Immunol, 2017. Epub. Disponível em: <https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(17)30673-5>. Acesso em: 13 set. 2017.
    2. GLAXOSMITHKLINE. A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients, 2017. In: CLINICAL TRIALS. Disponível em: <https://clinicaltrials.gov/ct2/show/NCT02712047>. Acesso em: 13 set. 2017.*
    *Apresentação oral: Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI). Peter Daley-Yates. Pôster número OA276, material não publicado.

    BR/RESP/0128/17d – Setembro/2017